Veloxis Pharmaceuticals Inc.

Calculating rank

USPTO Granted Patents = 9

% Expired Patents = 22.2

Trademarks = 2

Forward Citations = 5

Loading Chart...

6 inventors (with patents filed for the assignee):

Per Holm (7 out of 36 patents)

Tomas Norling (4 out of 22 patents)

Robert D Gordon (3 out of 15 patents)

4. Anne-Marie Lademann (3 out of 6 patents)

5. William J Polvino (2 out of 15 patents)

6. Nikolaj Skak (2 out of 11 patents)

9 patents: Sort by Forward Citations

1. 12403095 - Stabilized tacrolimus composition (2025-09-02),

2. 12083103 - Tacrolimus for improved treatment of transplant patients (2024-09-10),

3. 11957666 - Regimen for suppressing organ rejection (2024-04-16),

4. 11419823 - Stabilized tacrolimus composition (2022-08-23),

5. 11141408 - Regimen for suppressing organ rejection (2021-10-12),

6. 11129815 - Solid dispersions comprising tacrolimus (2021-09-28),

7. 11123331 - Tacrolimus for improved treatment of transplant patients (2021-09-21),

8. 11110081 - Tacrolimus for improved treatment of transplant patients (2021-09-07),

9. 11077096 - Modified release compositions comprising tacrolimus (2021-08-03),

Company Overview

Veloxis Pharmaceuticals Inc. is a specialty pharmaceutical company that develops and commercializes medical solutions for people with serious or life-threatening diseases. Their focus is on transplantation and their lead product, Envarsus XR (tacrolimus), is a once-daily immunosuppressive medication for kidney transplant recipients. Veloxis is committed to improving patient outcomes through innovative therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

9 Patents

#21 in Cary, NC

#674 in North Carolina

#32,605 in US

Cary, NC, United States of America